Last reviewed · How we verify

NCT06167447

Evaluation of the Presence and Effects of Kinesiophobia in Multiple Sclerosis

Completed Last updated 12 December 2023
What this trial tests

trial testing questionnaire and examination in Multiple Sclerosis in 90 participants. Completed in 30 June 2021.

Timeline
1 January 2021
Primary endpoint
1 May 2021
30 June 2021

Quick facts

Lead sponsorGazi University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment90
Start date1 January 2021
Primary completion1 May 2021
Estimated completion30 June 2021
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Gazi University

Who can join

Adults 18 to 65, any sex, with Multiple Sclerosis or Kinesiophobia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study was to evaluate the presence of kinesiophobia in multiple sclerosis and to investigate the effect of kinesiophobia on physical activity, functional status, quality of life and depression.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

Other Gazi University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06167447.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing